Browse > Article

Dendritic Cell Based Cancer Immunotherapy: in vivo Study with Mouse Renal Cell Carcinoma Model  

Lee, Hyunah (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Choi, Kwang-Min (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Baek, Soyoung (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Hong-Ghi (Division of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Jung, Chul-Won (Division of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
IMMUNE NETWORK / v.4, no.1, 2004 , pp. 44-52 More about this Journal
Abstract
Background: As a potent antigen presenting cell and a powerful inducer of antigen specific immunity, dendritic cells (DCs) are being considered as a promising anti-tumor therapeutic module. The expected therapeutic effect of DCs in renal cell carcinoma was tested in the mouse model. Established late-stage tumor therapeutic (E-T) and minimal residual disease (MRD) model was considered in the in vivo experiments. Methods: Syngeneic renal cell carcinoma cells (RENCA) were inoculated either subcutaneously (E-T) or intravenously (MRD) into the Balb/c mouse. Tumor cell lysate pulsed-DCs were injected twice in two weeks. Intraperitoneal DC injection was started 3 week (E-T model) or one day (MRD model) after tumor cell inoculation. Two weeks after the final DC injection, the tumor growth and the systemic immunity were observed. Therapeutic DCs were cultured from the bone marrow myeloid lineage cells with GM-CSF and IL-4 for 7 days and pulsed with RENCA cell lysate for 18 hrs. Results: Compared to the saline treated group, tumor growth (E-T model) or formation (MRD model) was suppressed in pulsed-DC treated group. RENCA specific lymphocyte proliferation was observed in the RENCA tumor-bearing mice treated with pulsed-DCs. Primary cytotoxic T cell activity against RENCA cells was increased in pulsed-DC treated group. Conclusion: The data suggest the possible anti-tumor effect of cultured DCs in established or minimal residual disease/metastasis state of renal cell carcinoma. Systemic tumor specific immunity including cytotoxic T cell activity was modulated also in pulsed-DC treated group.
Keywords
Dendritic cells; anti-cancer immunotherapy; renal cell carcinoma;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Steinman RM, Cohn ZA: Identificaion of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137;1142-1162, 1973   DOI   ScienceOn
2 Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392;245-252, 1998   DOI   ScienceOn
3 Inaba K, Young JW, Steinman RM : Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells. J Exp Med 166;182-194, 1987   DOI   ScienceOn
4 Annual Report of the Central Cancer Registry in Korea, Central Cancer Registry Center, Ministry of Health and Welfare p42, 2001
5 Gregorian SK., Battisto JR. : Immunosuppression in murine renal cell carcinoma II. Identification of responsible lymphoid cell phenotypes and examination of eliminatin of suppression. Cancer Immunol Immunothe 31(6);335-341, 1990   DOI   ScienceOn
6 Inaba K, Inaba M, Deguchi M, Hagi K, Yasumizu R, Ikehara S, Muramatsu S, Steinman RM: Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex calss II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci USA 90;3038-3042, 1993   DOI   ScienceOn
7 Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-. J Exp Med 179;1109, 1994   DOI
8 Kalinski P, Schuitemarker JH, Hilkens CM, Wierenga EA, Kapsenberg ML: Final maturation of dendritic cells id associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability ofmature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 162(6);3231-3236, 1999
9 Young Robert C: Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? The New England Journal of Medicine 338(18);1305-1306, 1998   DOI   ScienceOn
10 Inaba K, Metlay JP, Crowley MT, Steinman RM: Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 172;631-640, 1990   DOI   ScienceOn
11 Hart DNJ: Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90(9);3245-3287, 1997.   PUBMED
12 Fernandez N et.al.: Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Medicine 5(4);405-410, 1999   DOI   ScienceOn
13 Divgi CR, Bander NH, Scott AM: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4;2729, 1998
14 Wu L: Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 98;3376-3382, 2001   DOI   ScienceOn
15 Steinman RM: Prospects for immunotherapy directed to the T cell receptor in human autoimmune disease. Ann N Y Acad Sci 636;147-153, 1991   DOI   PUBMED
16 Inaba K, Inaba M, Romani N, Aya H, Dequchi M, Ikehara S, Steinman RM: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176(6);1693-1702, 1992   DOI   ScienceOn
17 Oosterwijk-Wakka J, Tiemessen D, Bleumer I, de Varies I, Jongmans W, Adema G, Debruyne F, de Mulder PH, Oosterwijk E, Mulders PF: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigen in combination with interleukin-2: A phase I study. J Immunother 25(6);500-508, 2002   DOI
18 Grabmaier K, Vissier JLM, De Weuert MCA: Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85;865, 2000   DOI   ScienceOn
19 Muller L, Provenzani C, Faul C, Pawelec G: Recognition of chronic myelogeneous leukemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells. Br J Haematol 112(3);740-748, 2001   DOI   ScienceOn
20 Holtl L, Rieser C, Papesh C: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161;777, 1999   DOI   ScienceOn
21 Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J: Imunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63;2127-2133, 2003
22 Lotze, M., Shurin, M., Davis, I., Amoscato, A., and Storkus, W.:Dendritic cell based therapy of cancer. Dendritic Cells in Fundamental and Clinical Immunology. Ricciardi-Castagnoli ed., Plenum Press, New York, USA, 1997
23 Rosenberg SA, Lotze MT, Mull LM: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316;889, 1987   DOI   ScienceOn
24 Ray PK, Raychaudhuri S, Allen P: Mechanism of regression of mammary adenocarcinomas in rats following plasma adsorption over protein A-containing staphylococcus aureus. Cancer Res 42;4970-4974, 1982.
25 Jonuleit H, Kuhn U, Muller G: Pro-inflammatory cytokines and prostaglandines induce maturaton of potent immunostimulatory dendritic cells under feta-calf-serum free conditions. Eur J Immunol 27(12); 3135-3142, 1999   DOI   ScienceOn
26 Gregorian SK, Battisto JR: Immunosuppression in murine renal cell carcinoma.I. Characterization of extent, severity and sources. Cancer Immunol Immunothe 31(6);325-334, 1990   DOI   ScienceOn
27 Shurin MR: Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 43;158, 1996   DOI   ScienceOn
28 Palucka K, Banchereau J: Dendritic cells: a link between innate and adaptive immunity. J Clin Immunol 19;12-25, 1999   DOI   ScienceOn
29 Kurokawa T, Oelke M, Mackensen A: Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 91;749, 2001   DOI   ScienceOn
30 Yoon HL, Singh KP, Ratner S, Reiners Jr JJ: Phorbol ester effects on splenic lymphocyte composition and cytotoxic T cell activities of SSIN mice: a strain deficient in CD8+ T cells. Carcinogenesis 17(12);2617-2624, 1996.   DOI   ScienceOn
31 Olweus J, BitMansour A, Warnke R: Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 94;12551-12556, 1997   DOI   ScienceOn
32 Medial Research Council Renal Cancer Collaborators: Interferon-$\alpha$ and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 353;14, 1999   DOI   ScienceOn
33 Flamand V, Sornasse T, Thielenabs K, Demanet C, Bakkus M, Bazin H, Thielemans C, Leo O, Urbain J, Moser M: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24;605-610, 1994   DOI   ScienceOn
34 Celluzzi C, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD:Peptide-pulsed dendritic cells induce antigen-specific, CTLmediated protective tumor immunity. J Exp Med 183;283-288, 1996   DOI   ScienceOn
35 Gitlitz B, Belldegrun A, Zisman A, Chao D, Pantuck A, Hinkel A, Mulders P, Moldawer N, Tso C, Figlin R: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 26(5);412-419, 2003   DOI
36 Steinman RM, Inaba K: Myeloid dendritic cells. J Leuk Biol 66(2);205-208, 1999   DOI
37 Palucka K, Banchereau J: Linking innate and adaptive immunity. Nat Med 5;868-870, 1999   DOI   ScienceOn